{"id":44723,"date":"2025-08-01T01:00:33","date_gmt":"2025-08-01T05:00:33","guid":{"rendered":"https:\/\/www.ncqa.org\/?page_id=44723"},"modified":"2025-09-19T17:05:00","modified_gmt":"2025-09-19T21:05:00","slug":"statin-therapy-for-patients-with-diabetes-spd-e","status":"publish","type":"page","link":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/","title":{"rendered":"Statin Therapy for Patients With Diabetes (SPD-E)"},"content":{"rendered":"<p><span data-contrast=\"auto\">The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. Two rates are reported:<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ol>\n<li><span data-contrast=\"auto\">Received Statin Therapy. Persons who were dispensed at least one statin medication of any intensity during the measurement period.<\/span><\/li>\n<li><span data-contrast=\"auto\">Statin Adherence 80%. Persons who remained on a statin medication of any intensity for at least 80% of the treatment period.<\/span><\/li>\n<\/ol>\n<h2>Why It Matters<\/h2>\n<p><span data-contrast=\"none\">Diabetes increases the risk of developing cardiovascular disease (CVD) by two to four times compared to those without diabetes <sup><a href=\"#ref-1\">1<\/a><\/sup>. CVD is the current leading cause of death among those with diabetes, accounting for two-thirds of deaths among those with type 2 diabetes (T2D) <sup><a href=\"#ref-2\">2<\/a><\/sup>. Often, diabetes increases risk to other cofactors that lead to an increased risk of heart disease including high blood pressure, too much low-density lipoprotein cholesterol (LDL-C), and high triglycerides <sup><a href=\"#ref-3\">3<\/a><\/sup>. High LDL-C in the body leads to a buildup of plaque in the walls of blood vessels. Plaque buildup creates an increased risk for cardiovascular events. Individuals with diabetes and above 40 years of age are at an even higher risk of CVD.<\/span><\/p>\n<p><span data-contrast=\"none\">Statins are a group of medications that lower LDL-C by blocking an enzyme in the liver that is needed to make cholesterol. The liver is then able to remove cholesterol from the blood, lowering the risk of atherosclerotic cardiovascular disease (ASCVD) <sup><a href=\"#ref-4\">4<\/a><\/sup> <sup><a href=\"#ref-5\">5<\/a><\/sup>. Management of cholesterol levels has a direct effect on overall health as well as risk of CVD. Guidelines recommend that patients with diabetes above the age of 40 should adhere to statin therapy <sup><a href=\"#ref-4\">4<\/a><\/sup>.<\/span><\/p>\n<h2><span data-teams=\"true\">Historical Results \u2013 National Averages<\/span><\/h2>\n<p><strong>Performance results for this measure are currently unavailable.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. Two rates are reported:\u00a0 Received Statin Therapy. Persons who were dispensed at least one statin medication of any intensity during the measurement period. Statin Adherence 80%. Persons [&hellip;]<\/p>\n","protected":false},"author":116,"featured_media":0,"parent":733,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-44723","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Statin Therapy for Patients With Diabetes (SPD-E) - NCQA<\/title>\n<meta name=\"description\" content=\"The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Statin Therapy for Patients With Diabetes (SPD-E) - NCQA\" \/>\n<meta property=\"og:description\" content=\"The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/\" \/>\n<meta property=\"og:site_name\" content=\"NCQA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/NCQA.org\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-19T21:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@NCQA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/\",\"url\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/\",\"name\":\"Statin Therapy for Patients With Diabetes (SPD-E) - NCQA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ncqa.org\/#website\"},\"datePublished\":\"2025-08-01T05:00:33+00:00\",\"dateModified\":\"2025-09-19T21:05:00+00:00\",\"description\":\"The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ncqa.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Report Cards\",\"item\":\"https:\/\/www.ncqa.org\/report-cards\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Health Plans\",\"item\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"State of Health Care Quality Report\",\"item\":\"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Statin Therapy for Patients With Diabetes (SPD-E)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ncqa.org\/#website\",\"url\":\"https:\/\/www.ncqa.org\/\",\"name\":\"NCQA\",\"description\":\"Measuring quality. Improving health care.\",\"publisher\":{\"@id\":\"https:\/\/www.ncqa.org\/#organization\"},\"alternateName\":\"National Committee for Quality Assurance\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ncqa.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ncqa.org\/#organization\",\"name\":\"NCQA\",\"alternateName\":\"National Committee for Quality Assurance\",\"url\":\"https:\/\/www.ncqa.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"contentUrl\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"width\":876,\"height\":673,\"caption\":\"NCQA\"},\"image\":{\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/NCQA.org\",\"https:\/\/x.com\/NCQA\",\"https:\/\/www.instagram.com\/ncqa_dc\/\",\"https:\/\/www.youtube.com\/@NcqaOrg\",\"https:\/\/www.linkedin.com\/company\/ncqa\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Statin Therapy for Patients With Diabetes (SPD-E) - NCQA","description":"The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/","og_locale":"en_US","og_type":"article","og_title":"Statin Therapy for Patients With Diabetes (SPD-E) - NCQA","og_description":"The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.","og_url":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/","og_site_name":"NCQA","article_publisher":"https:\/\/www.facebook.com\/NCQA.org","article_modified_time":"2025-09-19T21:05:00+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@NCQA","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/","url":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/","name":"Statin Therapy for Patients With Diabetes (SPD-E) - NCQA","isPartOf":{"@id":"https:\/\/www.ncqa.org\/#website"},"datePublished":"2025-08-01T05:00:33+00:00","dateModified":"2025-09-19T21:05:00+00:00","description":"The percentage of persons 40\u201375 years of age during the measurement period with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.","breadcrumb":{"@id":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/statin-therapy-for-patients-with-diabetes-spd-e\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ncqa.org\/"},{"@type":"ListItem","position":2,"name":"Report Cards","item":"https:\/\/www.ncqa.org\/report-cards\/"},{"@type":"ListItem","position":3,"name":"Health Plans","item":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/"},{"@type":"ListItem","position":4,"name":"State of Health Care Quality Report","item":"https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/"},{"@type":"ListItem","position":5,"name":"Statin Therapy for Patients With Diabetes (SPD-E)"}]},{"@type":"WebSite","@id":"https:\/\/www.ncqa.org\/#website","url":"https:\/\/www.ncqa.org\/","name":"NCQA","description":"Measuring quality. Improving health care.","publisher":{"@id":"https:\/\/www.ncqa.org\/#organization"},"alternateName":"National Committee for Quality Assurance","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ncqa.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ncqa.org\/#organization","name":"NCQA","alternateName":"National Committee for Quality Assurance","url":"https:\/\/www.ncqa.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","contentUrl":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","width":876,"height":673,"caption":"NCQA"},"image":{"@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/NCQA.org","https:\/\/x.com\/NCQA","https:\/\/www.instagram.com\/ncqa_dc\/","https:\/\/www.youtube.com\/@NcqaOrg","https:\/\/www.linkedin.com\/company\/ncqa\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/44723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/users\/116"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/comments?post=44723"}],"version-history":[{"count":0,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/44723\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/733"}],"wp:attachment":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/media?parent=44723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}